Business Context and Reporting Period
This Form 8-K filing by West Pharmaceutical Services, Inc. (WST) is dated July 21, 2025. The report discloses a significant executive leadership change involving the appointment of a new Chief Financial Officer and the transition of the outgoing CFO to an advisory role.
Key Financial Metrics
This filing does not contain operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
Executive Appointment
- New CFO: Robert McMahon appointed as Senior Vice President & Chief Financial Officer, effective August 4, 2025.
- Outgoing CFO: Bernard Birkett is retiring as CFO and will serve as Senior Advisor to the CEO through December 31, 2025.
Compensation Package for Robert McMahon
- Base Salary: $800,000 annually.
- Annual Incentive: Target bonus of 80% of base salary ($640,000), prorated for 2025.
- Sign-on Cash Bonus: $3,115,000 (subject to a two-year repayment clawback if employment terminates early).
- Sign-on Replacement Equity: $4,200,000 grant date fair value (comprised of $3.0M RSUs, $0.7M stock options, and $0.5M PSUs).
- Initial Long-Term Incentive (LTI): $3,000,000 grant date fair value to be granted on August 11, 2025 (50% PSUs, 25% stock options, 25% RSUs).
- Relocation: Standard benefits including up to $10,000 miscellaneous payment.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. The primary contingency noted is the repayment obligation for the sign-on cash bonus if Mr. McMahon's employment ends within two years for reasons other than death, disability, constructive termination, or termination without cause.
Investor Verification Checklist
- Verify the exact vesting schedule and performance metrics for the $3.0M Initial LTI and $4.2M Replacement Equity Grant.
- Confirm the specific terms of the "Constructive Termination" and "Cause" definitions in the Offer Letter (Exhibit 10.1) to understand clawback triggers.
- Review the transition plan details for Bernard Birkett's advisory role to ensure continuity in financial reporting.
- Check subsequent filings for the actual grant date and share count of the equity awards mentioned.